In contrast, if you've got (say) three months to live, the prospect of an extra few months with a reasonable quality of life, if probably something many people would take.
In contrast, if you've got (say) three months to live, the prospect of an extra few months with a reasonable quality of life, if probably something many people would take.
I can't speak about FDA, but I can speak about NICE and the Cancer Drugs Fund.
NICE was set up to look at the cost effectiveness of medications and treatments. They were refusing to recommend new cancer drugs. This was politically tricky, so the Cancer Drugs Fund was set up to provide novel meds.
We spent over £1bn on it, and most of the drugs provided no meaningful benefit and caused harm. https://www.bmj.com/content/357/bmj.j2097
You'd need to explore the data behind the individual approvals to comment on statistical validity. But without going that deep, you can be assured that the FDA is generally pretty conservative, and employs very robust statistical methodology.
We don't know how many patients received the 72 drugs approved over a ten year period but we do know the potential customer base for the drugs is massive. Millions of people could have taken the drugs, you could easily get a statistically significant result.